Clinical trial NCT05993143: Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Official title: A Multicentre, Phase III, Double-blind, Randomised, Parallel, Placebo-controlled Trial to Assess Efficacy and Safety of Early Administration of Ivermectin During 3 Consecutive Days to Prevent SARS CoV-2 (COVID-19) Hospitalisation in Adults Older Than 50 Years of Age
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: COVID-19
SARS-CoV-2
Keywords: ivermectin
Lead sponsor: Insud Pharma
Sponsor class: INDUSTRY
First posted: 2023-08-15
Enrollment: 249
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to assess the efficacy of early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 hospitalisation in adults older than 50 years of age. Secondary objectives include assessing the efficacy of an early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 disease progression in adults older than 50 years of age and evaluating the safety and tolerability of ivermectin in SARS-CoV-2 infected adults older than 50 years of age.

Detailed description: This is a randomised, double-blind, placebo-controlled, multicentre trial in parallel groups. During the screening/enrollment phase (Visit 1.1 to Visit 1.3) informed consent will be obtained and the screening procedures will be performed. A rapid antigen-based test will be offered to all patients who do not have a polymerase chain reaction (PCR) or a rapid antigen-based test result at screening (each of these tests may be considered a part of the standard procedure of the site). Eligible subjects will be randomised 1:1 to receive ivermectin or placebo. The subjects will be dispensed investigational product (IP), based on their body weight, and will take the first dose of IP at site. The subjects will receive portable pulse oximeters for peripheral capillary oxygen saturation (SpO2) monitoring at home. The treatment phase will last 3 days and include an on-site Visit 1.3 and phone call Visits 2 and 3 which will be performed on the following 2 days. PCR test or rapid antigen test results will be communicated to subjects as soon as available. Subjects with negative COVID-19 PCR test or rapid antigen test results will be withdrawn from the trial unless they have a positive rapid antigen test or COVID-19 PCR test result a few days later. The subjects will be followed up until Day 28.

During the follow-up, the subjects will have phone call Visits 4 to 9 every other day, followed by Visit 10 after one week (Day 21). The subjects will be asked to measure oxygen saturation as well as body temperature during all phone call visits and report the respective results to the investigator. The on-site Visit 11 is the last visit (Day 28). The subjects will return IPs (including empty and partially empty containers) and pulse oximeters.

In addition, the subjects will be provided with a contact number available 24/7 to contact the investigator if their condition worsens. In case of health condition worsening (dyspnoea, fever \[body temperature ≥ 37.8°C\] lasting for more than 6 days, SpO2 ≤ 95% or any other worsening criteria based on the investigator's judgement) confirmed during the phone call visit, the subjects will have an unscheduled visit at the site.

The subjects will be hospitalised if they fulfill any of the following criteria: pneumonia confirmed by chest X-ray; SpO2 ≤ 94% or partial pressure of oxygen in blood (PO2) \< 80 mmHg in gasometry; respiratory frequency \> 20 rpm; fever (body temperature ≥ 37.8°C) for more than 6 days plus one of the following analytic parameters: C-reactive protein (CRP) \> 5 mg/dL, ferritin \> 500 ng/mL or D dimer \> 700 ng/mL. If there is any other condition that requires hospitalisation as per investigator judgement, the condition has to be documented in detail in the subject's file including a description whether the hospitalisation was performed due to SARS-CoV-2 infection.

Eligibility criteria: Inclusion Criteria:

1. Male or female adult \> 50 years of age
2. SARS-CoV-2 infection diagnosed either through a rapid antigen-based test or an RNA based reverse-transcription polymerase chain reaction (RT-PCR) diagnostic test performed in nasopharyngeal sample
3. Onset of COVID-19 symptoms \< 120 hours (5 days) prior to screening
4. Written informed consent
5. For females of childbearing potential only: They must declare that they did not intend to become pregnant in the last month prior to screening and they do not intend to become pregnant for one month following the last IP administration. For males who have partners of childbearing potential: Willing to use condoms until 3 months after last IP intake.
6. Negative result for urine pregnancy test (women of childbearing potential only)

Exclusion Criteria:

1. Intake of Ivermectin within 30 days before screening
2. Routine intake of antivirals, including antiretroviral treatment
3. Allergy, hypersensitivity or contraindication to Ivermectin, metabolites or excipients
4. Subjects with symptoms of disease severity (dyspnoea, SpO2 ≤ 94%)
5. Subjects requiring hospitalisation for any reason.
6. Epidemiological risk or suspicion of being infected by Loa loa or other filariases
7. Previous enrolment in this trial or participation in any other drug investigational trial within the past 30 days (or five half-lives of IP whichever is longer) prior to screening
8. Weight \< 50 kg
9. Pregnancy or lactation
10. Inability to take oral medications
11. At least one of the following acute/chronic disease or deficiency:

    1. History of bone marrow transplant or haematopoietic systems diseases
    2. Moderate or severe liver disease (Child Pugh score ≥ B or ALT \[alanine transaminase\] or AST \[aspartate transaminase\] \> 3 times upper limit as determined at screening visit), severe cholestasis, cirrhosis or severe hepatic failure
    3. Transplanted patient under immunosuppressive treatment, disease that may need immunosuppressive treatments or other medical conditions that under the judgement of investigator would not benefit the patient to be included (including but not limited to psoriasis, G6PD (glucose-6-phosphate dehydrogenase) deficiency, porphyria, history of diverticulosis, seizure disorder, concurrent malignancy requiring chemotherapy, ongoing skin infection (e.g. pyodermitis) or evidence of current tuberculosis including latent untreated tuberculosis)
    4. Ophthalmological or recent/ongoing neurological diseases
12. Active cardiac disease or a history of cardiac dysfunction including any of the following:

    1. History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to screening
    2. History of congestive heart failure (New York Heart Association functional classification III-IV)
13. Concomitant use of barbiturates, sodium oxybate, valproic acid or warfarin
14. Laboratory abnormalities relevant for the trial, including but not limited to: neutropenia \< 500/mm3, thrombocytopenia \< 100,000/mm3
15. Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the subject because of participation in the study, affect the ability of the subject to participate in the study or impair interpretation of the study data
16. Employees of the investigator or clinical trial site, with direct involvement in the proposed trial or other studies under the direction of that investigator or clinical trial site, as well as family members of the employees or the principal investigator
17. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities

Primary outcomes:
measure: Hospitalisation due to SARS-CoV-2
timeFrame: day 1 to day 28
Secondary outcomes:
measure: Change in subjects' clinical status
timeFrame: day 1, 2, 3, 4, 6, 8, 10, 12, 14, 21 and 28
measure: Occurrence of any adverse event related to Ivermectin treatment
timeFrame: day 1, 2, 3, 4, 6, 8, 10, 12, 14, 21 and 28
Other outcomes:
Locations:
city: El Ejido
country: Spain
facility: Hospital de Poniente
state: Almeria
city: Badalona
country: Spain
facility: Hospital Universitari Germans Trias i Pujol
state: Barcelona
city: Granollers
country: Spain
facility: Hospital General de Granollers
state: Barcelona
city: Logroño
country: Spain
facility: Hospital San Pedro
state: La Rioja
city: Boadilla del Monte
country: Spain
facility: HM Montepríncipe
state: Madrid
city: Móstoles
country: Spain
facility: HM Puerta del Sur
state: Madrid
city: Torrelodones
country: Spain
facility: HM Torrelodones
state: Madrid
city: Pamplona
country: Spain
facility: Clínica Universidad de Navarra
state: Navarra
city: A Coruña
country: Spain
facility: Complejo Hospitalario Universitario A Coruña-CHUAC
city: Barcelona
country: Spain
facility: Centro de Atención Primaria Les Corts
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
city: Madrid
country: Spain
facility: Hospital Universitario de la Princesa
city: Madrid
country: Spain
facility: Clínica Universidad de Navarra - Madrid
city: Madrid
country: Spain
facility: Hospital Clínico San Carlos
city: Madrid
country: Spain
facility: HM Sanchinarro
city: Pamplona
country: Spain
facility: Complejo Hospitalario de Navarra
city: Salamanca
country: Spain
facility: Complejo Asistencial Universitario de Salamanca
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen de la Macarena
city: Tarragona
country: Spain
facility: Hospital Universitari de Tarragona Joan XXIII
Study officials:
References: